Actualités réglementaires
25 sept. 2026•1 min de lecture
FDA Discontinues Testosterone Enanthate Injectable Products (ANDA083667)
The FDA has discontinued two injectable testosterone enanthate products from Watson Labs, listed under ANDA083667.
Actualités réglementaires
19 sept. 2026•1 min de lecture
FDA Accepts ANDA084026 for Watson Labs' Chlorothiazide 500 mg Oral Tablet (Discontinued)
The FDA has processed application ANDA084026 for Watson Labs' oral chlorothiazide 500 mg tablet, currently listed as discontinued.
Actualités réglementaires
19 sept. 2026•1 min de lecture
FDA Approves ANDA 085767 for Phendimetrazine Tartrate 35 mg Tablet (Watson Labs)
The FDA has approved ANDA 085767 for a 35 mg oral tablet of phendimetrazine tartrate submitted by Watson Labs; the product is listed as discontinued.
Actualités réglementaires
16 sept. 2026•1 min de lecture
FDA Approves Methyclothiazide Tablet (ANDA 088750)
The FDA has approved ANDA 088750 for a 2.5 mg oral tablet of methyclothiazide submitted by Watson Labs; the product is listed as discontinued.
Actualités réglementaires
15 sept. 2026•1 min de lecture
FDA Approves ANDA 085231 for Pyrilamine Maleate Oral Tablet by Watson Labs
The FDA granted approval for ANDA 085231, an oral tablet containing 25 mg pyrilamine maleate, submitted by Watson Labs. The product is listed as discontinued.
Actualités réglementaires
13 sept. 2026•1 min de lecture
FDA Lists Diphenhydramine Hydrochloride Injection (ANDA083533) as Discontinued
Watson Labs' diphenhydramine hydrochloride injectable (product 001) is recorded by the FDA under ANDA083533 as discontinued and not a reference drug.
Actualités réglementaires
13 sept. 2026•1 min de lecture
FDA Approves ANDA081213 for ESTROPIPATE Oral Tablet
The FDA has granted approval (ANDA081213) for Watson Labs' ESTROPIPATE 0.75 mg oral tablet, with several labeling and manufacturing submissions approved.
Actualités réglementaires
10 sept. 2026•1 min de lecture
FDA Lists Watson Labs' COBAVITE Injection (ANDA083064) as Discontinued
FDA records indicate that Watson Labs' injectable product COBAVITE, containing 1 mg/mL cyanocobalamin, is listed as discontinued under ANDA083064.
Actualités réglementaires
9 sept. 2026•1 min de lecture
FDA Issues ANDA Approval for Watson Labs' Procaineamide Hydrochloride Oral Capsule (ANDA083795)
The FDA has approved an ANDA (ANDA083795) for Watson Labs' oral capsule containing 250 mg of procaineamide hydrochloride. The product is listed as discontinued.
Actualités réglementaires
9 sept. 2026•1 min de lecture
FDA Announces Discontinuation of Watson Labs Potassium Chloride Injection (ANDA 086210)
The FDA records show that Watson Labs' potassium chloride injectable (3 mEq/mL) under ANDA 086210 is listed with a discontinued marketing status.
Actualités réglementaires
9 sept. 2026•1 min de lecture
FDA Approves ANDA085790 for Isoniazid 100 mg Tablet by Watson Labs
The FDA has approved ANDA085790 for an oral 100 mg Isoniazid tablet submitted by Watson Labs. The product is currently listed as discontinued.
Actualités réglementaires
9 sept. 2026•1 min de lecture
FDA Lists ANDA087397 for Watson Labs BETHANECHOL CHLORIDE Tablet (Discontinued)
FDA records ANDA087397 for Watson Labs' oral tablet BETHANECHOL CHLORIDE 50 mg, currently marked discontinued.